Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Publication|Articles|November 22, 2024
- Fall 2024
- Volume 18
- Issue 02
Fall 2024 Quiz: Test Your Pharmacy Knowledge!
This quiz was created in collaboration with PTCE™.
Advertisement
What was the first massed produced commercial drug?
Articles in this issue
almost 2 years ago
Pharmacy Students Using TikTok to Take Learning to the Next Levelalmost 2 years ago
Q&A: Reducing Mental Health Stigma Starts in Pharmaciesalmost 2 years ago
Half of Pharmacy Technicians Feel Fulfilled in Their Current Rolealmost 2 years ago
Student Exchange Program Crafts Cultural Competency for Pharmacistsalmost 2 years ago
Overcoming Failure as a Recent Pharmacy Graduatealmost 2 years ago
Technology in the Classroom Helps Shape Tomorrow’s Pharmacy Leadersabout 2 years ago
Understanding the Burnout Crisis Among Student Pharmacistsabout 2 years ago
Pharmacist Provider Status Is Growing. Now What?Advertisement
Related to this article
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
5